Roche explores degrader-antibody conjugates to support its oncology pipeline

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates for cancer, with Roche obtaining exclusive rights to selected targets and a deal that includes a US$20 million upfront payment and more than US$1 billion in potential milestones and tiered royalties.

Roche has entered a collaboration with C4 Therapeutics to develop degrader-antibody conjugates for cancer treatment. The approach pairs targeted protein degradation with antibody-drug conjugation to explore a new oncology drug format. Under the agreement, Roche will select antibodies, conjugate them to degrader payloads, and lead preclinical, clinical and commercial execution for chosen programs. Financial terms reported include a US$20 million upfront payment and over US$1 billion in potential milestone payments plus tiered royalties. Key details: - The article mentions Roche Holding (SWX:ROP) and a collaboration with C4 Therapeutics focused on degrader-antibody conjugates. - The reported deal grants Roche exclusive rights to selected oncology targets. - The partnership combines targeted protein degradation with antibody-drug conjugation and may use C4 Therapeutics' TORPEDO platform. - Reported financial terms include a US$20 million upfront payment and more than US$1 billion in potential milestones and tiered royalties. - The article notes Roche's role in selecting antibodies and owning downstream development and commercial steps, and it references competitors such as Novartis, Merck and AstraZeneca. Summary: If the programs progress through preclinical and clinical development and gain regulatory approval, the collaboration could broaden the types of modalities available within Roche's oncology portfolio. Undetermined at this time.